lidocaine has been researched along with berotek in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (25.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (50.00) | 29.6817 |
2010's | 2 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Kleisbauer, JP; Orehek, J; Vesco, D | 1 |
Kurgan, J | 1 |
2 trial(s) available for lidocaine and berotek
Article | Year |
---|---|
Attenuation of bronchofiberscopy-induced cough by an inhaled beta 2-adrenergic agonist, fenoterol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Bronchoscopy; Cough; Fenoterol; Fiber Optic Technology; Humans; Lidocaine; Male; Smoking | 1988 |
[Possibility of prevention of histamine-induced bronchospastic reaction with fenoterol, ipratropium bromide and lidocaine in patients with chronic bronchitis].
Topics: Adult; Aerosols; Aged; Atropine Derivatives; Bronchial Spasm; Bronchitis; Chronic Disease; Clinical Trials as Topic; Ethanolamines; Female; Fenoterol; Histamine; Histamine Antagonists; Humans; Ipratropium; Lidocaine; Middle Aged | 1985 |
6 other study(ies) available for lidocaine and berotek
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |